Discontinuation report CABLIVI
| Report ID | 247940 |
| Drug Identification Number | 02496194 |
| Brand name | CABLIVI |
| Common or Proper name | CAPLACIZUMAB |
| Company Name | SANOFI-AVENTIS CANADA INC |
| Market Status | MARKETED |
| Active Ingredient(s) | CAPLACIZUMAB |
| Strength(s) | 11MG |
| Dosage form(s) | POWDER FOR SOLUTION KIT |
| Route of administration | SUBCUTANEOUS INTRAVENOUS |
| Packaging size | 1 vial/box |
| ATC code | B01AX |
| ATC description | |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | 2025-01-14 |
| Actual discontinuation date | 2025-01-14 |
| Remaining supply date | |
| Discontinuation status | Discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Company contact information | email: CAINTERNET@sanofi.com Telephone: 1-800-265-7927 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v2 | 2025-01-16 | French | Compare |
| v1 | 2025-01-16 | English | Compare |
Showing 1 to 2 of 2